Editorial Board

doi : 10.1016/S2588-9311(22)00148-1

Volume 5, Issue 5, October 2022, Pages i-ii

Buy The Package and View The Article Online

Contents

doi : 10.1016/S2588-9311(22)00149-3

Buy The Package and View The Article Online

Reconciling Discordance Between Prostate Biopsy Histology and Magnetic Resonance Imaging Suspicion – Implementation of a Quality Improvement Protocol of Imaging Re-review and Reverse-fusion Target Analysis

SrinathKotamartia1Rajan T.Guptaabc1BangchenWangdDenisSéguieraeZoeMichaelaDylanZhangbMichael R.AbernacJiaotiHuangcdThomas J.Polascikac

doi : 10.1016/j.euo.2022.06.007

Buy The Package and View The Article Online

Addition of Docetaxel to Androgen Receptor Axis–targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis

SoumyajitRoyab†RashidSayyidc†FredSaaddYilunSuneKatherineLajkoszfMichaelOnggZacharyKlaassenhShawnMaloneiDaniel E.SprattjChristopher J.D.Wallisk‡Scott C.Morgani‡

doi : 10.1016/j.euo.2022.06.003

Buy The Package and View The Article Online

Double or Triple Trouble in Metastatic Hormone-sensitive Prostate Cancer?

LouiseKostosaDeclan G.MurphybcArun A.Azadac

doi : 10.1016/j.euo.2022.07.001

Buy The Package and View The Article Online

Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group

Wei ShenTanabGarySteinbergcJ. AlfredWitjesdRogerLieShahrokh F.ShariatfgMorganRouprethMarkoBabjukiTrinity J.BivalacquajSarah P.PsutkakStephen B.WilliamslMichael S.CooksonmJuanPalounAshish M.Kamato

doi : 10.1016/j.euo.2022.05.005

Buy The Package and View The Article Online

Intermediate-risk Non–muscle-invasive Bladder Cancer: Time To Tidy Up the Mess?

FrancescoSoriaPaoloGontero

doi : 10.1016/j.euo.2022.07.003

Buy The Package and View The Article Online

Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial

BoDaiabcd†ShengZhangbcde†Fang-NingWanabcd†Hong-KaiWangabcd†Jun-YuZhangabcdQi-FengWangbcdfYun-YiKongbcdfXue-JunMabcdgMiaoMobhYaoZhuabcdXiao-JianQinabcdGuo-WenLinabcdDing-WeiYeabcd

doi : 10.1016/j.euo.2022.06.001

Buy The Package and View The Article Online

Prostatectomy in Patients with Oligometastatic Hormone-sensitive Prostate Cancer? Not Yet

PierreBlanchardaAndrew J.Vickersb

doi : 10.1016/j.euo.2022.07.005

Buy The Package and View The Article Online

Radical Prostatectomy or Radiotherapy in Oligometastatic Prostate Cancer: Is It Nearly Time To Call It a Draw?

MarkusGraefenaStevenJoniaub

doi : 10.1016/j.euo.2022.08.004

Buy The Package and View The Article Online

EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy

StefanoFantiabAlbertoBriganticLouiseEmmettdKarimFizazieSilkeGillessenfgKarolienGoffinhBoris A.HadaschikiKenHerrmannjJolantaKunikowskakTobiasMaurerlStevenMacLennanmNicolasMottetnDeclan G.MurphyoDaniela E.Oprea-LagerpJoe M.O'SullivanqWim J.G.OyenrstOlivierRouvièreuvOliverSartorw…AndersBjartellabac

doi : 10.1016/j.euo.2022.05.003

Buy The Package and View The Article Online

Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer

Carissa E.ChuaJanet E.CowanaPeter E.LonerganaSamuel L.WashingtonIIIaVittorioFasulobClaire M.de la CalleaKatsutoShinoharaaAntonio C.WestphalenacPeter R.Carrolla

doi : 10.1016/j.euo.2020.11.007

Buy The Package and View The Article Online

Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study

Andrew T.Lenisa†AydinPoolia†Patrick M.LecaTaylor Y.SadunaDavid C.JohnsonabCedricLebaclecWolfgang P.FendlerdMatthiasEibereJohannesCzerninaefRobert E.Reiteraf‡JeremieCalaisaefg‡

doi : 10.1016/j.euo.2020.08.012

Buy The Package and View The Article Online

Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial

Johannes AlfredWitjesaMatthew D.GalskybJürgen E.GschwendcEdwardBroughtondJuliaBravermandFedericoNasroulahdMarioMaira-ArcedXiaomeiYeeLingShieShienGuoeMelissaHamiltondDean F.Bajorinf

doi : 10.1016/j.euo.2022.02.003

Buy The Package and View The Article Online

Quality of Life Data in CheckMate 274: Does It Move the Needle?

Cristiane DecatBergerotaSandyLiubPauloBergerotaSumanta K.Palc

doi : 10.1016/j.euo.2022.03.008

Buy The Package and View The Article Online

Worldwide Distribution, Risk Factors, and Temporal Trends of Testicular Cancer Incidence and Mortality: A Global Analysis

JunjieHuangaSze ChaiChanaMan SingTinaXianjingLiubVeeleah Ting-TingLokcChun HoNgaiaLinZhangdeDon EliseoLucero-PrisnoIIIfgWanghongXuhZhi-JieZhengiPeter Ka-FungChiujkAnthony Chi-FaiNgjDmitryEnikeevlDavidNicolmPhilippe E.SpiessnPilarLagunaoJeremy Yuen-ChunTeohjkMartin C.S.Wongadi

doi : 10.1016/j.euo.2022.06.009

Buy The Package and View The Article Online

Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma

GéraldinePignotaAntoineThiery-VuilleminbLaurenceAlbigèscJochenWalzaHervéLangdLoïcBalssaeBastienParierfLionnelGeoffroisgKarimBensalahhFriederikeSchlürmanniSylvainLadoirejPierreBigotkDelphineBorchiellinilOphélieCassutomConstanceThibaultnAlexandreIngelsoVéroniqueSaldanapGuilhemRoubaudq…PhilippeBarthélémyt

doi : 10.1016/j.euo.2022.07.002

Buy The Package and View The Article Online

A Swinging Pendulum: Bringing Back Cytoreductive Nephrectomy in the Era of Immune Checkpoint Inhibition

MaximilianPallaufabYasserGedcNirmishSinglaac

doi : 10.1016/j.euo.2022.07.009

Buy The Package and View The Article Online

Newly Diagnosed Oligometastatic Prostate Cancer: Current Controversies and Future Developments

NicolaFossatiaGianlucaGiannarinibStevenJoniaucMichielSedelaardPrasannaSooriakumaranefMartinSpahnghMorganRouprêtiEAU Section of Oncological Urology (ESOU) Board

doi : 10.1016/j.euo.2020.11.001

Buy The Package and View The Article Online

Re: Stefano Fanti, Alberto Briganti, Louise Emmett, et al. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy. Eur Urol Oncol. 2022;5:530–6: Extended Use of PSMA PET/CT in Candidates for Focal Therapy

EgestaLopciaGiovanniLughezzanibcVittorioFasulobcMassimoLazzerib

doi : 10.1016/j.euo.2022.06.006

Buy The Package and View The Article Online

Erratum to “Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)� [Eur Urol Oncol 2021;4:543–52]

Michael J.Morrisab†Jose MauricioMotaa†‡KristineLacunabPatrickHildencMartinGleavedMichael A.CarduccieFredSaadfErica D.CohnaJulieFilipenkogGlennHellercNealShorehAndrew J.ArmstrongiHoward I.Scherab

doi : 10.1016/j.euo.2022.08.001

Buy The Package and View The Article Online